Human Papilloma Virus (HPV)

Newest HPV Vaccine Protects Against 9 Strains

A vaccine to prevent five additional strains of human papillomavirus (HPV) than the current quadrivalent (4-strain) HPV vaccine was approved yesterday by Food and Drug Administration.
Gardasil 9, manufactured by Merck Sharp & Dohme Corp, was approved for females aged 9 to 26 and males aged 9 to 15. The additional strains according to the FDA, can potentially prevent up to 90 percent of cervical, vulvar, vaginal and anal cancers.

Merck wins FDA approval for Gardasil follow-up

Merck's ($MRK) Gardasil follow-up is here, meaning blockbuster sales figures are likely on the way. But the bad news is that they'll come at the expense of the world's second-best-selling shot.
On Wednesday, the FDA approved Gardasil 9, which prevents cervical, vulvar, vaginal and anal cancers caused by the four HPV types its predecessor protects against, as well as an additional 5 types--31, 33, 45, 52 and 58--that cause approximately one-fifth of cervical cancers, according to the FDA.

Free HPV vaccination program sees upward trend in those vaccinated

The launch of a temporary free-of-charge human papillomavirus (HPV) vaccination program in Europe was well accepted and showed an increase in the percentage of those that took action and got the HPV vaccine from 17 percent to a 75 percent.
The increase was most notable among descendants and immigrants.

Reseach shows hope for natural vaccines to control disease

Those infected with the herpes virus have new hope in controlling outbreaks and the research garnering them hope could also help others with other immune diseases, according to the Center for the Biology of Chronic Disease (CBCD).


From the US Centers for Disease Control and Prevention (US CDC) website:

Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Angola to Introduce HPV Vaccine By 2015

Angola has announced the introduction of human papilloma virus vaccination (HPV) in 2015, as part of its national immunisation programme.
The fact was announced Thursday in Luanda by the Health minister, José Van-Dúnem.
The Health minister was speaking at the opening of 10th International Conference on Treatment of Cancer in Africa, called "AORTIC PALOP", going between 02 and 03 October, under the Oncology Center.
The official stressed that the HPV vaccine can combat cervix and oropharynx cancers.

Call to offer HPV vaccine to boys

It comes amid pressure to extend vaccination to all adolescent boys in the UK, in line with other countries.
The committee is expected to focus initially on whether to offer the vaccine to men who have sex with men, who may be at higher risk.
But a coalition of health experts and campaigners say vaccinating all boys aged 12 to 13 would save lives.

CIRC : la période d'essais des vaccins contre le VPH peut être considérablement réduite

Un rapport rédigé par un groupe de travail des experts, conjointement réuni par le Centre international de recherche sur le Cancer (CIRC), agence spécialisée sur le cancer de l'Organisation mondiale de la santé (OMS), et l'Institut national du Cancer des Etats-Unis, agence sanitaire et scientifique américaine, montre comment l'évaluation et l'autorisation des vaccins prophylactiques contre le virus du papillome humain (VPH) pourraient être considérablement accélérées, a annoncé lundi le CIRC sur son site Internet.